227 related articles for article (PubMed ID: 35326082)
41. Primary Vitreoretinal Lymphoma Presenting as a Posterior Capsule Plaque.
Hussain RM; Garoon RB; Duker JS; Dubovy SR; Albini TA
Ophthalmic Surg Lasers Imaging Retina; 2018 Sep; 49(9):732-734. PubMed ID: 30222812
[TBL] [Abstract][Full Text] [Related]
42. BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY.
Kanavati S; Ottensmeier C; Foria V; Krishnan R
Retin Cases Brief Rep; 2018 Summer; 12(3):184-187. PubMed ID: 27828902
[TBL] [Abstract][Full Text] [Related]
43. Next-Generation Sequencing of Vitreoretinal Lymphoma by Vitreous Liquid Biopsy: Diagnostic Potential and Genotype/Phenotype Correlation.
Kwak JJ; Lee KS; Lee J; Kim YJ; Choi EY; Byeon SH; Chang WS; Kim YR; Kim JS; Shin S; Lee ST; Kim SS; Lee CS
Invest Ophthalmol Vis Sci; 2023 Nov; 64(14):27. PubMed ID: 37975847
[TBL] [Abstract][Full Text] [Related]
44. INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA: Case Series.
Guneri Beser B; Demirci H
Retina; 2024 Feb; 44(2):353-359. PubMed ID: 37883576
[TBL] [Abstract][Full Text] [Related]
45. Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma.
de Hoog J; Dik WA; Lu L; Heezen KC; Ten Berge JC; Swagemakers SMA; van der Spek PJ; van Dongen JJM; van der Velden VHJ; Rothova A; Langerak AW
Acta Ophthalmol; 2019 Sep; 97(6):626-632. PubMed ID: 30688042
[TBL] [Abstract][Full Text] [Related]
46. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
47. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes.
Levasseur SD; Wittenberg LA; White VA
JAMA Ophthalmol; 2013 Jan; 131(1):50-5. PubMed ID: 23307208
[TBL] [Abstract][Full Text] [Related]
48. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
49. A Nine-Year Analysis of Practice Patterns, Microbiologic Yield, and Clinical Outcomes in Cases of Presumed Infectious Endophthalmitis.
Feng HL; Robbins CB; Fekrat S
Ophthalmol Retina; 2020 Jun; 4(6):555-559. PubMed ID: 32387054
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome.
Coupland SE; Bechrakis NE; Anastassiou G; Foerster AM; Heiligenhaus A; Pleyer U; Hummel M; Stein H
Graefes Arch Clin Exp Ophthalmol; 2003 Oct; 241(10):860-70. PubMed ID: 14605902
[TBL] [Abstract][Full Text] [Related]
51. Clinical Features Predictive of Survival in Patients With Vitreoretinal Lymphoma: Analysis of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Porcu P; Martinez NL; Glass J; Mashayekhi A; Shields CL
Asia Pac J Ophthalmol (Phila); 2020; 9(2):110-116. PubMed ID: 31923035
[TBL] [Abstract][Full Text] [Related]
52. Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.
Kim RY; Park JH; Kim M; Park YG; Cho SG; Park YH
PLoS One; 2021; 16(11):e0260469. PubMed ID: 34813633
[TBL] [Abstract][Full Text] [Related]
53. Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.
Cheng CL; Yeh PT; Fang WQ; Ma WL; Hou HA; Tsai CH; Lin CP; Tien HF
Cancer Med; 2023 Apr; 12(7):8102-8111. PubMed ID: 36602288
[TBL] [Abstract][Full Text] [Related]
54. Optic Nerve Infiltration in Systemic Metastatic Retinal Lymphoma (SMRL): Multimodal Imaging and Challenges in Diagnosis.
Mohd Fauzi Yap MFB; Mohd Zain A; Tumian NR; Palaniappan S; Nasaruddin RA; Md Din N
Ocul Immunol Inflamm; 2021 Apr; 29(3):479-484. PubMed ID: 32967510
[TBL] [Abstract][Full Text] [Related]
55. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.
Jiang T; Gu J; Liu S; Chang Q
BMC Ophthalmol; 2022 Sep; 22(1):375. PubMed ID: 36127675
[TBL] [Abstract][Full Text] [Related]
56. Logistic regression models of cytokines in differentiating vitreoretinal lymphoma from uveitis.
Tian S; Chen K; Xiao J; Zhou X; Shi H; Li Y; Huang H; Ma Y; Chen B; Wang Q; Guan M
J Clin Lab Anal; 2022 Oct; 36(10):e24689. PubMed ID: 36098043
[TBL] [Abstract][Full Text] [Related]
57. Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population.
Mahajan S; Nijhawan R; Rajwanshi A; Karkhur S; Mulkutar S; Dogra M; Lal V; Gupta V; Gupta A
Ocul Immunol Inflamm; 2017 Oct; 25(5):633-638. PubMed ID: 27003620
[TBL] [Abstract][Full Text] [Related]
58. The molecular hallmarks of primary and secondary vitreoretinal lymphoma.
Bonzheim I; Sander P; Salmerón-Villalobos J; Süsskind D; Szurman P; Gekeler F; Spitzer MS; Steinhilber J; Kohler E; Büssgen M; Schittenhelm J; Salaverria I; Campo E; Coupland SE; Quintanilla-Martinez L; Fend F
Blood Adv; 2022 Mar; 6(5):1598-1607. PubMed ID: 34448823
[TBL] [Abstract][Full Text] [Related]
59. Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma.
Cho BJ; Kim DY; Park UC; Lee JY; Yoon YH; Yu HG
Ocul Immunol Inflamm; 2018; 26(3):365-371. PubMed ID: 29394118
[TBL] [Abstract][Full Text] [Related]
60. Clinical features predictive of vision loss in patients with vitreoretinal lymphoma: a single tertiary center experience.
Kim M; Suh H; Park YG; Park YH
Sci Rep; 2023 Mar; 13(1):4478. PubMed ID: 36934118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
